Daily Cosmetic Research Analysis
Evidence synthesis and mechanistic safety studies stood out today. A meta-analysis confirms botulinum toxin type A effectively reduces sweat in primary axillary hyperhidrosis with fewer adverse effects versus alternatives, while two in vitro human-skin studies quantify dermal permeation and metabolism of widely used cosmetic chemicals (PFAS and C12-15 alkyl benzoate), informing exposure risk and non-animal safety assessment.
Summary
Evidence synthesis and mechanistic safety studies stood out today. A meta-analysis confirms botulinum toxin type A effectively reduces sweat in primary axillary hyperhidrosis with fewer adverse effects versus alternatives, while two in vitro human-skin studies quantify dermal permeation and metabolism of widely used cosmetic chemicals (PFAS and C12-15 alkyl benzoate), informing exposure risk and non-animal safety assessment.
Research Themes
- Evidence synthesis for aesthetic therapeutics
- Cosmetic ingredient dermal absorption and metabolism
- PFAS exposure from personal care products
Selected Articles
1. Efficacy and Safety of Botulinum Toxin Type A in Primary Axillary Hyperhidrosis: A Meta-analysis and Systematic Review.
Across 12 RCTs (n=904), botulinum toxin type A significantly reduced axillary sweat versus placebo and had fewer adverse effects compared with other treatments, while efficacy versus alternatives was similar. Study quality was appraised using Cochrane methods with subgroup and sensitivity analyses.
Impact: This meta-analysis consolidates RCT evidence clarifying BTX-A’s efficacy and safety in primary axillary hyperhidrosis, supporting evidence-based decision-making and patient counseling.
Clinical Implications: BTX-A can be offered as an effective option for primary axillary hyperhidrosis with fewer adverse events relative to other treatments. Clinicians should discuss comparable efficacy to alternatives, potential durability, and patient-reported outcomes when selecting therapy.
Key Findings
- BTX-A reduced sweat versus placebo by 116.12 (95% CI 92.68–139.57; P<0.05) on gravimetric measurement.
- Compared with other treatments, BTX-A showed no significant difference in sweat reduction (26.14 [-26.8, 79.07]; P=0.333) or HDSS (-0.85 [-1.20, 0.50]; P=0.413).
- Pain scores were comparable to other treatments (-0.41 [-1.11, 0.29]; P=0.456).
- BTX-A had fewer side effects than other treatments (0.18 [0.07, 0.43]; P<0.05).
Methodological Strengths
- PRISMA-compliant and PROSPERO-registered methodology
- Cochrane risk-of-bias assessment with subgroup and sensitivity analyses
Limitations
- Heterogeneity across trials and comparators may affect pooled estimates
- Limited long-term comparative data on durability and quality-of-life outcomes
Future Directions: Head-to-head RCTs with longer follow-up comparing BTX-A against alternative modalities, including cost-effectiveness and patient-reported outcomes.
BACKGROUND: The clinical efficacy of botulinum toxin type A (BTX-A) injections for the treatment in primary axillary hyperhidrosis is a subject of ongoing debate. This study aims to consolidate and analyze the available evidence regarding the use of BTX-A as a therapeutic intervention for this conclusion. METHOD: This study was conducted in accordance with PRISMA guidelines and registered with PROSPERO. We included RCTs on BTX-A injections for PAH, comparing it to placebo or other treatments. A comprehensive literature search was conducted in multiple databases up to May 2024. Out of identified articles, some underwent full-text review and were included in the qualitative and quantitative synthesis. Statistical analyses were done using RevMan5.4, and study quality was assessed with the Cochrane risk of bias tool. Subgroup and sensitivity analyses were also conducted. RESULT: Twelve studies met our inclusion criteria (n = 904). BTX-A injection showed greater sweat reduction compared to placebo by gravimetric measurement (116.12 [92.68-139.57]; P < 0.05). BTX-A injection showed comparable sweat reduction to other treatments by gravimetric measurement (26.14 [- 26.8, 79.07]; P = 0.333) and HDSS (- 0.85 [- 1.20, 0.50], P = 0.413). The pain score of BTX-A injection is comparable to other treatments (- 0.41 [- 1.11, 0.29], P = 0.456). BTX-A injection exhibited fewer side effects compared to other treatments (0.18 [0.07, 0.43], P < 0.05). CONCLUSION: In primary axillary hyperhidrosis, BTX-A injection significantly reduces sweat production compared with placebo, and there is no statistically significant difference compared with other treatments. BTX-A injection had less fewer side effects compared with other treatments. LEVEL OF EVIDENCE I: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
2. Decorative cosmetics and skin care products contribute significantly to short-chain perfluoroalkyl carboxylates exposure.
Using 3D human skin equivalents, the study quantified dermal permeation of 14 PFAS, finding highest cumulative permeation for PFBA and lowest for PFTeDA. Higher exposure concentrations increased permeation, highlighting that decorative cosmetics and skin care can meaningfully contribute to short-chain PFCA exposure.
Impact: Provides mechanistic, quantitative evidence of PFAS dermal permeation from personal care exposures, informing risk assessment and regulatory strategies for cosmetic formulations.
Clinical Implications: Dermatologists and public health practitioners should recognize potential dermal PFAS exposure via cosmetics, especially short-chain PFCAs, and counsel patients on product choices while regulators consider limits and disclosure for PFAS in personal care products.
Key Findings
- Among 14 PFAS, PFBA showed the highest cumulative dermal permeation in 3D-HSE, while PFTeDA showed the lowest.
- Increasing exposure concentration (e.g., from 312.5 ng/cm²) led to increased PFAS permeation.
- Findings indicate decorative cosmetics and skin care products can significantly contribute to short-chain PFCA exposure via skin.
Methodological Strengths
- Use of in vitro 3D human skin equivalents to model human dermal permeation
- Evaluation of a panel of 14 PFAS with concentration-dependent assessment
Limitations
- In vitro model without in vivo/biomonitoring validation limits direct extrapolation
- Abstract lacks detailed kinetics and formulation matrix effects
Future Directions: Conduct in vivo dermal pharmacokinetic and biomonitoring studies, assess formulation matrices, and integrate data into quantitative risk assessments for short-chain PFAS.
Research on dermal exposure of per- and polyfluoroalkyl substances (PFAS) in personal care products is limited. Here, we investigated the permeation of 14 PFAS using in vitro 3D-human skin equivalents (3D-HSE). Results revealed that perfluorobutanoic acid (PFBA) exhibited the highest cumulative permeation, while perfluorotetradecanoic acid (PFTeDA) showed the lowest. Increasing the exposure concentration from 312.5 ng/cm
3. Dermal absorption and metabolism of [14C]-C12 alkyl benzoate in Finsolv TN in human skin in vitro.
In vitro human skin studies with radiolabeled C12 alkyl benzoate in Finsolv TN found low dermal absorption (2.97% dermally absorbed) with extensive metabolism to benzoic acid and aliphatic alcohols, and no parent detected in receptor fluid. Results support exposure-led, non-animal safety assessments for this widely used emollient.
Impact: Provides quantitative human-skin data on dermal absorption and metabolism of a ubiquitous cosmetic emollient, refining risk assessment and supporting REACH-aligned non-animal testing strategies.
Clinical Implications: Findings suggest low systemic exposure from topical use, with skin esterases converting C12-15 alkyl benzoate to benign metabolites; this informs counseling on ingredient safety and occupational exposure management.
Key Findings
- Dermally absorbed value was 2.97%, with absorbed dose 0.41%, dermal delivery 0.97%, and potentially absorbable dose 2.20%.
- [14C]-benzoic acid (>93%) was detected in receptor fluid while parent C12 alkyl benzoate was not, indicating extensive first-pass metabolism in skin.
- Phenyl acetate esterase assays confirmed esterase activity in donor skins.
- C12 alkyl benzoate was validated as a worst-case representative constituent for the mixture via preliminary GC–MS penetration testing.
Methodological Strengths
- Flow-through diffusion cell with dermatomed human skin and radiolabel tracing
- Concurrent metabolism assessment and enzymatic activity confirmation
Limitations
- In vitro setting without in vivo confirmation limits external validity
- Single homolog tested for detailed TK, with 24-hour collection window
Future Directions: Expand dermal TK to other alkyl chain lengths and real-world formulations; assess inter-individual variability and occupational exposure scenarios.
C12 alkyl benzoate is present in the commercial emollient cosmetic ingredient C12-15 alkyl benzoate (Finsolv TN). Finsolv TN is a mixture of linear and branched esters of benzoic acid and aliphatic alcohols where linear C12 alkyl benzoate is a representative homolog with the shortest alkyl C-chain and lowest molecular weight. A preliminary non-GLP in vitro skin penetration study which monitored dermal bioavailability of all C12-15 alkyl benzoate constituents using GC-MS was carried out which demonstrated C12 alkyl benzoate could be considered a worst-case representative constituent to determine dermal absorption of the overall substance. Subsequently, [14C]-C12 alkyl benzoate was mixed into Finsolv TN, and applied, neat (10 µl/cm2), to dermatomed human skin mounted in a flow-through diffusion cell system. Receptor fluid was collected up to 24 h postdose and the skin was decontaminated at 8 h postdose. The absorbed dose, dermal delivery, potentially absorbable dose and dermally absorbed value of [14C]-C12 alkyl benzoate were 0.41%, 0.97%, 2.20%, and 2.97%, respectively. Metabolism during absorption was assessed in skin from the same donors, with no C12 alkyl benzoate detected in the receptor fluid, although the primary metabolite, [14C]-benzoic acid (>93%), was detected. A phenyl acetate esterase assay confirmed the presence of esterase activity in the donor skins used. Therefore, this study confirmed that dermal exposure of C12-15 alkyl benzoate (Finsolv TN) results in an absorbed dose of 2.97% completely metabolized to benzoic acid and aliphatic alcohol(s) in human skin. These findings indicate that a more in-depth investigation and assessment of toxicokinetic behavior (specifically for occupational exposures via the skin) provide opportunities to develop exposure-led strategies to avoid unnecessary animal testing allowing registrants to fulfill obligations to adhere to the "last resort" principle under REACH.